Sermorelin: The GHRH Peptide With a Real Clinical Record
A clear, evidence-first look at sermorelin (GHRH 1-29): what it is, what the human trials actually show, and where the anti-ageing hype outruns the data.
By Research Rats Editorial TeamReviewed by Research Rats Editorial Team
Evidence profile
Assessed 2026-06-13A GHRH(1-29) peptide with a genuine clinical record — a sound GH-provocation test and a second-line paediatric GH-deficiency treatment — but the popular adult anti-ageing/body-composition use is essentially unstudied, the GH effect wanes (tachyphylaxis), and supply is now compounded or grey-market. WADA-prohibited.
Well-established GHRH(1-29); the active fragment of human GHRH.
Classic, well-characterised GHRH biology.
Real human data for medical use (diagnostic test; paediatric GH-deficiency RCTs); adult anti-ageing rests on two small 1997 trials of a related analogue.
Proven for GH-deficiency diagnosis and second-line paediatric growth (consistently behind recombinant GH); optimisation use unproven.
Former approved drug with paediatric/adult trial safety; mild AEs, but antibodies and tachyphylaxis documented.
Formerly FDA-approved (Geref, 1997–2008; withdrawn for commercial reasons); now compounded/off-label.
Confident for the medical record; weak for the adult-optimisation case.
WADA-prohibited (GHRH analogue); the discussed use is off-label via compounding or grey-market.
Bars show the state of evidence, not desirability. A strong rating on any axis does not mean a compound is safe, effective, or recommended. Human evidence is often limited. Not medical advice.
What to know before reading further
Free for everyone — safety, evidence and regulatory context are never members-only.
Evidence context
A GHRH(1-29) peptide with a genuine clinical record (a former FDA-approved drug) — sound as a GH-provocation test and a second-line paediatric treatment — but the popular adult anti-ageing/body-composition use is essentially unstudied.
Safety snapshot
A former approved drug with documented mild adverse effects, but chronic off-label adult use is unstudied; the GH effect wanes (tachyphylaxis), anti-GHRH antibodies are documented, and a theoretical GH/IGF-1 proliferation concern applies.
Regulatory & legality
Withdrawn from the US market (for commercial reasons) and now compounded/off-label; WADA-prohibited, and supply is compounded or grey-market 'research' material.
Where claims can exceed the evidence
Proven for GH-deficiency diagnosis and paediatric growth (behind recombinant GH); adult 'optimisation' benefit is unproven.
This article does not provide dosing, protocol, administration, sourcing, stack, or self-experimentation guidance, or personalised medical advice. It is educational and non-prescriptive — the evidence profile describes the state of research, not an individual decision.
Overview
Sermorelin is one of the few "research peptides" with a genuine clinical pedigree. It is GHRH(1-29)-NH2 — the shortest fragment of human growth hormone-releasing hormone that keeps full biological activity [1] — and it was an actual FDA-approved drug (brand name Geref) from 1997 until its manufacturer pulled it for commercial reasons in 2008. That history matters, because it means sermorelin's core claims rest on real human data rather than rodent studies and forum reports.
The honest summary: the strong evidence is narrow. Sermorelin reliably stimulates growth hormone (GH) release when used as a diagnostic test [1], and it modestly improves growth in some GH-deficient children — while consistently underperforming recombinant GH (somatropin) head-to-head [1][3][4]. The popular use today — compounded "anti-ageing" and body-composition support in healthy adults — is essentially unstudied in large modern trials. Two things you should keep in view from the outset: the GH-stimulating response tends to fade with chronic dosing [9], and most people now obtain sermorelin off-label through compounding or "research-only" suppliers.
Disclaimer. For educational and research purposes only. Not medical advice. We do not sell peptides or compounds.
This detailed research report is available to members
Research Rats is an 18+ educational research platform. Member-only content provides structured evidence interpretation only. It is not medical advice, dosing guidance, protocol guidance, sourcing guidance, cycle design, stack design or treatment advice.
Free safety information remains available where possible.
To continue, create an account or log in and agree to the Terms of Website Use, Privacy Notice, Cookie and Site Technologies Policy, and Medical, Health and Research Disclaimer.
Member access does not provide medical advice, dosing advice, sourcing advice, protocol guidance or treatment recommendations. How Research Rats works
[ Related research ]
CJC-1295 With DAC: The GHRH Analog That Made It to Human Trials
An evidence-first look at CJC-1295 with DAC: real human PK/PD data, how albumin-binding extends its half-life to days, and why development was halted.
CJC-1295 Without DAC (Mod GRF 1-29): What the Evidence Actually Shows
A plain-English, evidence-first look at CJC-1295 without DAC: what it is, why its half-life is short, what the research does and does not show, and the real risks.
GHRP-2 (Pralmorelin): What the Evidence Actually Shows
GHRP-2 reliably triggers a growth hormone pulse and ramps up hunger, but the physique and longevity claims rest on weak, mostly acute data.
GHRP-6: The Original GH-Releasing Peptide That Started It All
GHRP-6 is the first GH-releasing hexapeptide and ghrelin-receptor agonist — strong acute GH evidence, robust hunger effect, but largely superseded by cleaner analogues.